New Chapter in Decade Long Patent Fight Among DNA Diagnostics Leaders

more+
less-

Enzo Life Science’s U.S. Patent No. 6,992,180 entitled “Oligo- or Polynucleotides Comprising Phosphate-Moiety Labeled Nucleotides” (“the ’180 patent”) issued in January of 2006.  The patent traces back to an application filed in June 1982.  After a series of continuation applications, a June 7, 1995 filing ultimately gave rise to the ’180 patent.  Because it was filed just before the GATT treaty effective date, the ‘180 patent will expire in 2023 — 17 years from the day the patent issued and 41 years after the original patent filing.

On January 30 of this year, Enzo sued Roche, Life Sciences, and Gen-Probe in the federal district court of Delaware, alleging that certain diagnostic probe products infringe the ’180 patent.  In particular, Enzo asserts that Roche’s HIV and hepatitis C diagnostic tests, Life Technologies’ TaqMan® line of assays, and Gen-Probe’s APTIMA® assays for chlamydia, gonorrhea, trichomoniasis, HPV, HIV, and hepatitis C all infringe the ’180 patent.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

more+
less-

Dechert LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×